×
Chemed Receivables 2010-2025 | CHE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Chemed receivables for the quarter ending March 31, 2025 were
$0.286B
, a
61.21% increase
year-over-year.
Chemed receivables for 2024 were
$0.171B
, a
5.7% decline
from 2023.
Chemed receivables for 2023 were
$0.182B
, a
30.2% increase
from 2022.
Chemed receivables for 2022 were
$0.139B
, a
1.6% increase
from 2021.
View More
Chemed Receivables 2010-2025 | CHE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Chemed receivables for 2024 were
$0.171B
, a
5.7% decline
from 2023.
Chemed receivables for 2023 were
$0.182B
, a
30.2% increase
from 2022.
Chemed receivables for 2022 were
$0.139B
, a
1.6% increase
from 2021.
Related Stocks
Company Name
Market
Cap
Quest Diagnostics (DGX)
$18.3B
DaVita (DVA)
$11.2B
Encompass Health (EHC)
$10.4B
Option Care Health (OPCH)
$5.3B
Elanco Animal Health (ELAN)
$4.2B
RadNet (RDNT)
$3.7B
Amedisys (AMED)
$3B
LifeStance Health (LFST)
$2.6B
Addus HomeCare (ADUS)
$1.8B
Astrana Health (ASTH)
$1.6B
U.S Physical Therapy (USPH)
$1B
Pennant (PNTG)
$907M
Aveanna Healthcare Holdings (AVAH)
$886M
Atai Life Sciences (ATAI)
$294M
Daxor (DXR)
$36M
Ontrak (OTRK)
$6M
MEDIROM Healthcare Technologies (MRM)
$4M
Psychemedics (PMD)
$0M